DDInter504 DDInter1376
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Desipramine {u} (Compound) resembles {v} (Compound) Aprindine
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Desipramine {u} (Compound) binds {v} (Gene) SLC22A2
Desipramine {u} (Compound) upregulates {v} (Gene) ALDOC
Desipramine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Desipramine {u} (Compound) downregulates {v} (Gene) HAT1
Desipramine {u} (Compound) causes {v} (Side Effect) Disturbance in sexual arousal
Desipramine (Compound) resembles Aprindine (Compound)
Desipramine (Compound) resembles Protriptyline (Compound)
Desipramine (Compound) binds SLC22A2 (Gene)
Desipramine (Compound) upregulates ALDOC (Gene)
Desipramine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Desipramine (Compound) downregulates HAT1 (Gene)
Desipramine (Compound) causes Disturbance in sexual arousal (Side Effect)